Supramolecular Pharmaceutics/Medicine;Supramolecular Biomaterials;Radiopharmaceuticals (and Radioactive/Heavy Elements Analysis and Control)
Dr. Ruibing Wang has multidisciplinary background and experience in Organic Chemistry, Supramolecular Chemistry/Materials, Radiopharmaceuticals and Interventional Medicine R&D. During his PhD studies at Queen’s University, he was among the earliest group of researchers to look into a group of novel macrocyclic molecules, cucurbiturils, and their supramolecular encapsulation of various guest molecules including drug molecules for stability and water-solubility enhancement. Due to his excellent thesis work, he was nominated for “Governor General Gold Medal” and subsequently received “Queen’s University Outstanding Thesis in Physical Sciences”. After graduation with PhD study and a brief postdoctoral stay at Queen’s, he moved to the Steacie Institute for Molecular Sciences at the National Research Council (NRC) of Canada as an Associate Research Officer for about two years, where he worked on fluorescent quantum dots development and studied their various applications including bioimaging. He was subsequently invited to join BTG International (Canada) as a Senior Scientist, where he had led various innovation and applied research projects around radiopharmaceuticals and interventional medicine development. Since late 2014, he has joined the University of Macau as an Assistant Professor in Pharmaceutical Sciences. He has been affiliated with the Editorial Office of Chinese Medicine (SCI-index journal, co-owned by ISCM and UM) as Deputy Director since 2016. His research interest has been mainly focused on supramolecular pharmaceutics and supramolecular medicine, and smart biomaterials, as well as radiopharmaceutical sciences. So far, he has published more than 110 peer-reviewed SCI papers with a total citation of around 2000 times and an H-index of 25 (Google Scholar).